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Abstract
Haemorrhagic fever with renal syndrome (HFRS) is endemic in Asia, Europe and Scandinavia, and is caused by infection with the
hantaviruses Hantaan (HTNV), Seoul (SEOV), Puumala (PUUV), or Dobrava (DOBV) viruses. We developed candidate DNA vaccines for
HFRS expressing the Gn and Gc genes of HTNV or PUUV and evaluated them in an open-label, single-centre Phase 1 study. Three groups of
nine participants each were vaccinated on days 0, 28 and 56 with the DNA vaccines for HTNV, PUUV, or a mixture of both vaccines using
the Ichor Medical Systems TriGridTM Intramuscular Delivery System. All vaccinations consisted of a total dose of 2.0 mg DNA in an injected
volume of 1 mL saline. For the combined vaccine, the mixture contained equal amounts (1.0 mg) of each DNA vaccine. There were no
study-related serious adverse events. Neutralizing antibody responses were measured by a plaque reduction neutralization test.
Neutralizing antibody responses were detected in ﬁve of nine and seven of nine individuals who completed all three vaccinations with the
HTNV or PUUV DNA vaccines, respectively. In the combined vaccine group, seven of the nine volunteers receiving all three vaccinations
developed neutralizing antibodies to PUUV. The three strongest responders to the PUUV vaccine also had strong neutralizing antibody
responses to HTNV. These results demonstrate that the HTNV and PUUV DNA vaccines delivered by electroporation separately or as a
mixture are safe. In addition, both vaccines were immunogenic, although when mixed together, more participants responded to the PUUV
than to the HTNV DNA vaccine.
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Introduction
Haemorrhagic fever with renal syndrome (HFRS) is caused by
infection with viruses in the Hantavirus genus, family Bunya-
viridae. HFRS presents with sudden fever, chills, nausea,
headache and backache. In severe cases, death can occur as
the result of vascular leakage leading to low blood pressure,
acute shock and renal failure. There are no US Food and
Drug Administration-licensed vaccines for HFRS, although
various inactivated vaccines have been developed, tested and
are in use in Asia, particularly in China [1]. We have
developed two plasmid DNA vaccines that together are
intended to protect against the four hantaviruses causing
most cases of HFRS: Hantaan (HTNV), Seoul (SEOV),
Puumala (PUUV), or Dobrava (DOBV) viruses. The vaccines
express the genes encoding the envelope glycoproteins, Gn
and Gc, of HTNV or PUUV. Neutralizing antibodies to Gn
and Gc have been shown to be sufﬁcient to passively protect
hamsters from infection with hantaviruses, and are believed
to be a key component of the protective immune response in
humans as well [2–6].
Although we showed that the HTNV and PUUV DNA
vaccines administered separately to hamsters elicited neu-
tralizing antibodies to both viruses, when they were delivered
as a mixture, antibody responses were detected only to
PUUV [7]. Because of this immune interference, for our
previous clinical study we delivered the vaccines separately.
That Phase 1 study included three cohorts of nine
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participants who were vaccinated by particle-mediated epi-
dermal delivery (PMED) with the HTNV vaccine, the PUUV
vaccine or both vaccines as separate administrations [8].
Results of the study showed that both vaccines were safe
with no study-related serious adverse events (SAEs) [8]. The
vaccines were also found to be immunogenic, with some
individuals developing very high levels of neutralizing antibod-
ies to HTNV or PUUV, including two participants who had
antibodies to both viruses. Nevertheless, the overall sero-
conversion rate (below 50%) following PMED delivery was
too low for further development [8].
Due to the limitations of the PMED technology, we sought a
more effective method to deliver the HTNV and PUUV DNA
vaccines. In our experience with DNA vaccine delivery
methods in animal studies, intramuscular electroporation
(IM-EP) has proven most effective for eliciting strong immune
responses against a variety of pathogens [7,9–11]. Moreover,
there are now extensive human safety data available for
electroporation delivery of DNA vaccines with almost 40
clinical studies currently listed at clinicaltrials.gov as being in
progress or completed.
Here we report the results of a Phase 1 clinical study of
the HTNV and PUUV DNA vaccines delivered by IM-EP using
Ichor Medical Systems TriGridTM Delivery system (TDS-IM).
As in the PMED study, we compare the individual and
combined vaccines in three cohorts; however, in the present
study the cohort receiving both vaccines received an equal
mixture of the HTNV and PUUV vaccines as a single
administration per dosing. This study, therefore, assesses
IM-EP as a possible means to improve the immunogenicity of
the HTNV and PUUV DNA vaccines and provides the ﬁrst
clinical information assessing mixed HTNV and PUUV DNA
vaccines.
Materials and Methods
Vaccines
Constructions of the HTNV and PUUV DNA vaccines
expressing the envelope glycoprotein genes were described
previously [5,12,13]. The vaccine plasmids were produced
under current Good Manufacturing Practices by Althea
Technologies, Inc. (San Diego, CA). The DNA was formulated
in phosphate-buffered saline. The ﬂow-cytometry-based in vitro
potency and stability assays were performed essentially as
described previously [8,14].
Clinical study participants
Healthy adult volunteers between the ages of 18 and 49 years
(inclusive) were recruited through the Walter Reed Army
Institute of Research (WRAIR) Clinical Trials Center, Silver
Spring, MD, USA. All recruiting and consent methods and
materials were compliant with current Good Clinical Practice
guidelines and approved by the Walter Reed Army Institute of
Research (WRAIR) Institutional Review Board. Data obtained
from all participants receiving at least one vaccination were
included in the safety statistical analysis. To exclude persons
with possible previous exposure to a hantavirus, serum
samples from all participants were screened for pre-existing
antibodies to HTNV and PUUV by ELISA using irradiated
antigen derived from HTNV- or PUUV-infected cells as
described previously [15].
Clinical study design overview
The study was sponsored by the The Surgeon General,
Department of the Army, under IND 14 828 using an
open-label, single-centre design with three vaccination groups
of nine participants each. Following consent and successful
screening, each participant was randomized using block
allocation in groups of three, with one member of each
block being assigned to each vaccine group according to a list
made before screening and enrolment by the study statisti-
cian. After all groups were full, additional participants were
enrolled as alternatives, and used in order of enrolment to ﬁll
any openings in the groups as they arose. One group received
the HTNV DNA vaccine, one group the PUUV DNA vaccine,
and one group an equal mixture of both vaccines. Vaccines
were administered to the medial deltoid muscles of partic-
ipants using the Ichor Medical Systems TDS-IM (Ichor Medical
Systems, Inc., San Diego, CA). All participants completing the
study were given a single injection of 2 mg DNA/1 mL PBS
on Days 0, 28 and 56 and were followed until Day 240.
Subjects failing to complete all three vaccinations within the
protocol-determined time-frame were replaced by an
alternative.
Safety assessments
Safety was assessed by evaluating local and systemic reactions
of the participants. The following endpoints were evaluated:
(1) the nature, frequency and severity of solicited adverse
events (AEs) occurring from the time of each injection
through to 14 days following the procedure; (2) the nature,
frequency and severity of unsolicited AEs from the time of the
ﬁrst injection through to 28 days following the ﬁnal injection;
and (3) the nature, frequency and severity of SAEs from the
time of the ﬁrst injection through to the end of the study.
The solicited AEs for this study included: local ﬁndings at site
of injection (redness, swelling, bruising, or pain), fever,
myalgia, muscle contractions, fatigue, headache, lymphade-
nopathy, axillary pain or discomfort, and tachypnoea. All AEs
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were assessed for severity by the investigator (Table 1). Any
Grade 4 AE was reported as an SAE. Safety laboratory
measurements included sodium, potassium, glucose, blood
urea nitrogen, creatinine, alkaline phosphatase, aspartate
aminotransferase, alanine aminotransferase, complete blood
count with differential, and urinalysis.
Immunogenicity assessment
Plaque reduction neutralization tests (PRNT) were performed
using Vero E6 cells as described previously, with minor
modiﬁcations [8,16,17]. Brieﬂy, for HTNV, monolayers were
stained 7 days after infection with neutral red and plaques
were counted within 4 days. For PUUV, monolayers were
ﬁxed 10 days after infection by the addition of 2 mL of 10%
formalin/well followed by 5–16 h incubation at room tem-
perature. The agarose overlay was removed and plaques
were visualized by immunostaining using horseradish perox-
idase-conjugated monoclonal antibody MAb-3d7 followed by
True Blue peroxidase substrate (KPL, Gaithersburg, MD,
USA). Blinded serum samples from participants were either
screened at a 1 : 20 dilution for HTNV or PUUV neutralizing
activity and those positive were then retested in duplicate to
determine endpoint PRNT50 titres; or alternatively, full
endpoint neutralizing antibody titres against both HTNV
and PUUV were determined in duplicate without pre-
screening.
Statistical methods
Descriptive analysis of safety and reactogenicity outcomes
included all participants who received at least one vaccination,
and for whom safety data were available. Summary tables were
created in which incidence, intensity and relationship to use of
investigational product of individual solicited signs, symptoms
and other events were delineated by study group, severity,
gender and overall. Unsolicited AEs and SAEs were analysed in
a similar fashion. For haematology and serum chemistry tests,
any clinically signiﬁcant change from baseline value was
identiﬁed. The median, interquartile range and normal values
for each of the laboratory values (as determined by the
contract laboratory) were reported for each treatment group
for each specimen collection point. The primary analysis
variable was the proportion of seropositive participants
(PRNT50 ≥20) at each scheduled time point for which blood
samples were taken and duration of seropositivity. Geometric
mean peak titres were also determined.
Results
Clinical participant population
The Phase 1 study included three randomized groups of nine
participants each, along with four alternatives, for a total of 31
participants. A total of 27 participants (nine per group)
completed the three-dose series; two participants (03 and 28)
received one dose of the mixed vaccines, and two participants
(04 and 07) received two doses of the HTNV vaccine (Fig. 1).
The 31 participants enrolled included 19 males and 12 females
between the ages of 20 and 49 years. Races enrolled included
African American, white, Asian and other. The ethnicities were
predominantly non-Hispanic/Latino (Table 2).
Vaccine safety assessment
All 31 participants who received at least one dose of vaccine
were evaluated for safety. No SAEs related to the vaccine or
study-related procedures were observed, and no participant
experienced a temperature greater than 37.7°C (99.8°F). The
most common solicited local AE was pain at the site of
injection, which was reported by 28 of the 31 participants, with
seven participants also showing bruising (Table 1). The next
most common solicited AEs were headache (eight participants)
and myalgia (described as muscle aches and reported by seven
participants) (Table 1). All study-related adverse events were
graded mild or moderate in severity. One participant was
found to have unrelated Grade 4 hypoglycaemia (44 mg/dL).
After exhaustive evaluation by an endocrinologist, it was
determined that this SAE was probably the result of an
unrecognized pre-existing condition.
TABLE 1. Solicited adverse events for each vaccination
group
Adverse event and Severitya
HTNV
2.0 mg
(n = 11)
PUUV
2.0 mg
(n = 9)
HTNV/
PUUV
1.0 mg
each
(n = 11)
n % n % n %
Redness at site of injection 0 0 1 11 2 18
Grade 1 (Mild) 0 0 1 11 2 18
Bruising at site of injection 0 0 4 44 3 27
Grade 1 (Mild) 0 0 3 33 2 18
Grade 2 (Moderate) 0 0 1 11 1 9
Pain at site of injection 10 91 8 89 10 91
Grade 1 (Mild) 6 55 2 22 7 64
Grade 2 (Moderate) 4 36 6 67 3 27
Myalgia 1 9 2 22 4 36
Grade 1 (Mild) 1 9 2 22 3 27
Grade 2 (Moderate) 0 0 0 0 1 9
Muscle contractions 1 9 0 0 1 9
Grade 1 (Mild) 1 9 0 0 1 9
Fatigue 3 27 1 11 2 18
Grade 1 (Mild) 3 27 1 11 1 9
Grade 2 (Moderate) 0 0 0 0 1 9
Headache 3 27 2 22 3 27
Grade 1 (Mild) 3 27 2 22 2 18
Grade 2 (Moderate) 0 0 0 0 1 9
Tachypnoea 1 9 0 0 1 9
Grade 1 (Mild) 1 9 0 0 1 9
Abbreviations: HTNV, Hantaan virus; PUUV, Puumala virus.
aGrade 1 (mild, does not interfere with routine activities); Grade 2 (moderate,
interferes with routine activities); Grade 3 (severe, unable to perform routine
activities); Grade 4 (hospitalization or Accident and Emergency Department visit
for potentially life-threatening event).
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In 95.1% of participants, the duration of the related adverse
events, as deﬁned as being probably or deﬁnitely related to
study vaccine, was 3 days or less. Related adverse events
reported in Group 3 volunteers who had received both
vaccines were of shorter duration than adverse events
reported in the two other groups. Six participants were found
to have mild (n = 4) to moderate (n = 2) anaemia deemed to
be possibly related to the study product. One individual had a
mild decrease in platelets that was determined to be possibly
related (137 cells 9 103/lL), although this volunteer’s prefac-
ing level was 142 cells 9 103/lL. There was no development
of renal insufﬁciency secondary to vaccine administration.
Vaccine immunogenicity
Subjects were vaccinated three times at Days 0, 28 and 56.
Blood samples were collected at seven time points: Days 0, 28,
56, 84, 140, 180 and 240. Of the four participants replaced with
alternatives, the two participants receiving a single dose of the
mixed vaccines did not develop neutralizing antibodies to either
HTNV or PUUV; however, the two participants receiving only
two HTNV vaccine doses (participants 4 and 7) nevertheless
developed HTNV neutralizing antibodies (Fig. 2a).
Seven of the eleven (64%) participants who received at least
two vaccinations with the HTNV DNA vaccine, developed
neutralizing antibodies (Fig. 2a). Three participants vaccinated
with the HTNV DNA vaccine developed neutralizing antibod-
ies after a single vaccination and the other four seroconverted
TABLE 2. Subject demographics
Total
number
% of
total
Subjects
Enrolled 31
Completed study
procedures
27 87
Withdrawn 4a 13
Total 31 100
Gender
Male 19 61
Female 12 39
Total 31 100
Age
18–19 years 0 0
20–29 years 8 26
30–39 years 9 29
40–49 years 14 45
Total 31 100
Race
African-American 15 48
Asian 1 3
Native Alaskan 0 0
Other 3 10
White 12 39
Total 31 100
Ethnicity
Hispanic/Latino 1 3
Not Hispanic/Latino 30 97
Total 31 100
aTwo participants were withdrawn for non-compliance. One participant withdrew
self. One participant was withdrawn due to a non-study related serious adverse
effect (hypoglycaemia).
Dose 1
Dose 2
Subjects in Group 1
2.0 mg HTNV Vaccine
N=11
Dose 3
Subjects in Group 1
2.0 mg HTNV Vaccine
N=11
Subjects in Group 2
2.0 mg PUUV Vaccine
N=9
Subjects in Group 3
1.0 mg HTNV Vaccine, 
1.0 mg PUUV Vaccine
N=9
Subjects Completing 
HTNV-PUUV Vaccine 
Study
N=27
Open label, single center
Adults age18-49 recruited
Subjects Randomized 
N = 31*
Subjects in Group 2
2.0 mg PUUV Vaccine
N=9
Subjects in Group 3
1.0 mg HTNV Vaccine, 
1.0 mg PUUV Vaccine
N=11
Subjects in Group 3
1.0 mg HTNV, 1.0 mg 
PUUV Vaccine
N=9
Subjects in Group 1
2.0 mg HTNV Vaccine
N=9
Subjects in Group 2
2.0 mg PUUV Vaccine
N=9
FIG. 1. Study design. Thirty-one participants received at least one vaccination. Two participants (ID:04,07) in the Hantaan virus (HTNV) vaccine
group were replaced after two doses, by participants 29 and 30. Subject 3 in the mixed vaccine group was replaced after the ﬁrst dose by participant
28, who was subsequently replaced after a single dose by participant 31.
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after the third vaccination. Peak titres were achieved at or
within 1 month of the ﬁrst positive sample collection. Titres in
all participants who developed neutralizing antibodies dropped
after peaking on Days 28 or 84. Three participants exhibited
neutralizing antibodies only at Day 84 (1 month after the third
vaccination). Two participants displayed cross-neutralizing
antibodies to PUUV and two participants displayed detectable
neutralizing antibodies to HTNV on the last day of testing
(Day 240) (see Table S1.)
Six of eight (75%) participants who received at least two
vaccinations with the PUUV DNA vaccine developed neutral-
izing antibodies to PUUV (Fig. 2b). The last participant had
neutralizing antibody titres to both PUUV (PRNT50 = 20) and
HTNV (PRNT50 = 80) at Day 0, even though a blood sample
prescreened by ELISA before vaccination was negative. This
same participant received an unsuccessful injection 1 month
earlier, during which the device malfunctioned and the
injectate remained in the syringe. Serum collected at that time
was negative for both HTNV and PUUV neutralizing
antibodies. The reason that the sample collected at the time
of the unsuccessful vaccination was negative for neutralizing
antibodies, but that the sample collected at the time of the ﬁrst
successful vaccination (Day 0) was positive remains unknown.
Nevertheless, this participant did show a rise in neutralizing
antibodies to PUUV after three successful vaccinations
(Fig. 2b, dotted line).
Two participants vaccinated with the PUUV DNA vaccine
developed a neutralizing antibody response after a single
vaccination (Fig. 2b). In those individuals, as observed for the
HTNV DNA vaccine, the third vaccination did not appear to
boost the response (see Table S2). Three additional
participants responded after the second vaccination and
one participant responded after the third vaccination
(Fig. 2b). Peak titres were achieved at or within 1 month of
the ﬁrst observed positive PRNT titre. All participants
seroconverting had measureable PRNT50 titres at three or
more sampling points with peak titres between Days 28 and
84 (Table S2). Of the six participants who developed
neutralizing antibodies to PUUV, all but one still had PRNT50
titres on the last day of testing (Day 240) (Fig. 2b, Table S2).
Two participants had low levels of HTNV cross-neutralizing
activity (Table S2).
Seven of nine (78%) of the participants vaccinated at least
twice with the mixed HTNV and PUUV DNA vaccines
developed neutralizing antibodies to PUUV (Fig 2d). The three
participants with the highest levels of neutralizing antibodies to
PUUV also developed neutralizing antibodies to HTNV
(Fig. 2c). Three additional participants had lower PRNT50
titres to PUUV, but did not have neutralizing antibodies against
HTNV (Fig 2c,d). Of the six participants who responded to
PUUV, one displayed a PRNT50 titre after one vaccination,
three after two vaccinations and two after three vaccinations.
(a) (b)
(c) (d)
FIG. 2. Neutralizing antibody titres measured by plaque reduction neutralization test (PRNT) in serum samples collected from participants
vaccinated with the Hantaan virus (HTNV) (a), Puumala virus (PUUV) (b), or a mixture of both (c, d) DNA vaccines. All participants were vaccinated
with 2 mg DNA in 1 mL saline per dosing by intramuscular electroporation. Subjects 4 and 7 received two vaccine doses and all other participants
received three doses. Subjects that did not have meaureable PRNT titres are not included in the graphs. Each symbol represents the PRNT50 titre for
participants listed in the legends. Arrows indicate vaccination days.
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One participant had a low level (PRNT50 = 28) response to
PUUV on Day 84, but not at any other time point. All samples
collected from this same person were negative for HTNV
neutralizing antibodies except at day 240 (PRNT50 = 20),
suggesting that this could be a false positive. Of the other three
participants who responded to the HTNV vaccine, two had
neutralizing antibodies after two vaccinations and one after
three vaccinations. All six of the participants that were positive
for PUUV still had detectable neutralizing antibodies to PUUV
on the last day of testing (Day 240). Likewise, the three
participants with HTNV neutralizing antibodies remained
positive on Day 240 (Fig. 2c,d; see Table S3).
Discussion
Despite very encouraging results in early-stage clinical studies
of DNA vaccines, there are as yet no DNA vaccines licensed
for human use. A considerable obstacle has been the
development of an effective means to deliver DNA vaccines
to humans. Of the delivery methods tested to date, IM-EP has
proven to be among the most effective means of eliciting
immune responses in laboratory studies and in early-phase
clinical studies of infectious disease as well as cancer targets
[18–21]. In the studies presented here, we used an Ichor
Medical Systems TDS-IM device, which uses disposable
cartridges of DNA delivered using automated DNA injection
and subsequent electroporation.
As neutralizing antibodies have been shown to be sufﬁcient
to passively protect hamsters from hantavirus infections, the
PRNT remains the most sensitive and meaningful assay that we
have to predict protective immunity [2–4,22]. Moreover, as a
result of the absence of an animal disease model for HFRS and
the expected difﬁculty of ﬁnding a study population of
sufﬁcient size to assess our vaccines in a traditional Phase 3
trial, correlating the PRNT response with protection might be
the only path of licensure for these vaccines. Based on PRNT
analysis of blood samples from vaccinated participants, we
determined that the overall seroconversion rates to the
individual HTNV and PUUV DNA vaccines were better in the
IM-EP Phase 1 study than in the earlier PMED Phase 1 study for
individuals receiving at least two doses of either vaccine; i.e.
64% versus 30% for the HTNV vaccine and 75% versus 44% for
the PUUV vaccine. The PUUV response in the group receiving
both vaccines was also higher in the IM-EP study (78%) as
compared to the PMED study (33%). These results suggest
that the IM-EP delivery method might be more efﬁcacious than
PMED; although, it should also be noted that because of the
intrinsic properties of the respective delivery methods, much
higher levels of DNA were delivered by IM-EP (2 mg) than by
PMED (8 lg) at each dosing. As PMED delivery requires
precipitation of DNA onto gold, it is not technically possible to
prepare a vaccine dose equivalent to what is possible with
IM-EP. A more appropriate comparison of PMED and EP
technologies might come from our planned studies, in which
we will deliver the hantavirus DNA vaccines by intradermal
(ID)-EP. With ID-EP technology, like PMED, the amount of
DNA that can be delivered per dose is much smaller than is
possible by IM-EP. In both the preclinical toxicity study in
rabbits (Schmaljohn et al., manuscript submitted) and the
Phase 1 study, cross-neutralizing antibody responses of
participants vaccinated with either the HTNV or PUUV
DNA vaccines were rare, but did occur. In both studies the
cross-PUUV PRNT50 titres were higher than the cross-HTNV
PRNT50 titres. These data conﬁrm our previous studies
indicating that both HTNV and PUUV DNA vaccines will be
required to provide comprehensive protection against HFRS.
In our earlier PMED study, we delivered the HTNV and
PUUV DNA vaccines separately, because of immune interfer-
ence that occurred when hamsters were vaccinated with a
mixture of the two vaccines [7]. Here, the HTNV and PUUV
vaccines were given as a 1 : 1 mixture as a single administra-
tion at each dosing both to rabbits in the preclinical toxicology
study and to humans in the Phase 1 study. It was clear in the
preclinical study that the mixed vaccines could elicit responses
to both HTNV and PUUV, but that the response to HTNV was
signiﬁcantly lower (p <0.0001) than the response obtained
when the HTNV DNA vaccine was given alone (data not
shown). In the Phase 1 study presented here, we also observed
possible interference as evidenced by a higher number of
participants developing neutralizing antibodies to PUUV than
to HTNV in the mixed vaccine group. Of note, the three
individuals receiving the mixed vaccines who did develop high
levels of neutralizing antibodies to HTNV were the same three
individuals with the highest responses to PUUV. Therefore,
although interference is probably still an issue, it is neither
absolute nor results in a lower neutralizing antibody response
in participants who do produce neutralizing antibodies.
In terms of safety, as in our previous study with these
vaccines, we observed no study-related SAE. The delivery
method was also generally tolerated. Although most of the
participants reported pain at the site of injection during
administration procedures, the initial discomfort resolved
within moments in the majority of cases. No participant
discontinued participation as a result of the procedure itself.
In conclusion, this study demonstrates that the DNA
vaccines that we developed for HTNV and PUUV delivered
using IM-EP are safe and are able to elicit neutralizing antibody
responses in the majority of human participants. Improving
upon the inconsistent levels of neutralizing antibodies achieved
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among the volunteers will remain a focus of our efforts.
Studies that we have planned include a Phase 2a dose ranging
study in which we will compare two doses and two schedules
of IM-EP delivery in a larger study population, as well as an
additional Phase 1 study in which we will compare IM-EP and
ID-EP delivery of the mixed vaccines. Both of those studies will
be performed with a genetically optimized HTNV component,
which we expect to obviate interference problems.
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